Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients-Reference-Cited by-同舟云学术

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients

Published:2019-02 Issue:2 Volume:139 Page:201-205
ISSN:0001-6489
Container-title:Acta Oto-Laryngologica
language:en
Short-container-title:Acta Oto-Laryngologica

Author:

Sato Hiroki¹,Tsukahara Kiyoaki¹,Okamoto Isaku¹,Katsube Yasuaki¹,Shimizu Akira¹,Kondo Takahito²,Hanyu Kenji²,Fushimi Chihiro³,Okada Takuro³,Miura Kouki³

Affiliation:

1. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;

2. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan;

3. Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Otorhinolaryngology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00016489.2018.1551623

Reference14 articles.

1. Chemotherapy in head and neck cancer

2. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

3. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers Version 2.2017 (2017).

5. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum resistance and sensitivity in recurrent/metastatic head and neck squamous cell carcinoma;Auris Nasus Larynx;2024-02

2. Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma;Anticancer Research;2022-10

3. 頭頸部癌免疫療法のエッセンス;Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo);2022-07-20

4. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma;Scientific Reports;2022-02-07

5. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy;In Vivo;2022